RESUMEN
Introduction: SARS-CoV-2 infection has affected more than 683 million people worldwide with 6.8 million deaths. Unfortunately, Bulgaria is one of the most severely affected European Union (EU) member-states with one of the highest mortality rates. Aim: The study aims to provide a description of the demographic characteristics, discharge rate, and fatality rate of COVID-19-diagnosed patients in one region of Central South Bulgaria in 2021. Materials and methods: A retrospective nested case series study was conducted among patients hospitalized with a confirmed diagnosis of SARS-CoV-2 infection between January 1st and December 31st, 2021. Anonymized patient data on age, sex, admission and discharge dates, treatment, and the outcome was collected from hospital electronic patient records and analyzed using descriptive statistics. Results: Data from 1630 (51% male) patients were identified. The mean age was 63.64 years (+or-15.23). 1342 (82%) of the patients were discharged. The mean age of the diseased was 70.88 years (+or-10.05). 1455 (89%) patients received only symptomatic therapy, 155 (10%) patients were treated with remdesivir (VekluryR), 11 (1%) patients were treated with casirivimab/imdevimab (RonapreveR) and 9 (1%) patients were administered regdanvimab (RegkironaR). Conclusions: The study results demonstrate that Bulgarian patients with COVID-19 were treated according to the best global and national evidencebased guidelines. Lethality and discharge rates are in concordance with global trends and outcomes.
RESUMEN
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are the main therapeutic alternatives in treating pain and inflammation among various populations. However, they are linked with some adverse reactions and drug interactions. This review aims to summarize the naproxen mechanism of action and place it in the therapeutic strategy. Naproxen is a reversible inhibitor of the pro-inflammatory enzyme cyclooxygenase (COX) used in clinical practice for control of pain of various origin, namely post-traumatic pain (distortion and sprain), post-operative pains (in traumatology, orthopedics, gynecology, maxillofacial surgery), gynecological pains (pain and discomfort at primary dysmenorrhea, after the introduction of an intrauterine coil, etc.), headache and toothache, prevention or treatment of migraine, spinal pains, extra-articular rheumatism. It has been established that the duration of pain relief after a single dose of naproxen is significantly greater than after the intake of ibuprofen-containing products of equal concentration in the post-operative period of dental intervention. Naproxen is recommended as a drug for the choice of the class of tNSAIDs also in many national therapeutic guidelines (England, Canada, Russia).